Trial Profile
A study of "Treat and Extend" therapy with Aflibercept in patient with neovascular age related macular degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Mar 2018
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 05 Mar 2018 New trial record